Trade group’s break from WuXi Apptec allows BIO to reset its lobbying approach under its new CEO but doesn’t negate the business and supply chain disruptions that biopharma would feel from the proposed legislation.

The US Senate moves closer to new legislation that would restrict Chinese "biotech companies of concern” from operating in the US, potentially causing broad and far-reaching impact.

A draft bill from the US House related to national security issues sent WuXi Biologics' shares tumbling over concerns around increased US scrutiny of Chinese firms, which a company clarification did little to dispel.  

Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.